Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1819 in Moderate-to-Severe Atopic Dermatitis (Phase II)
CTR20255128Phase 2Active
- Sponsor
- Hengrui Therapeutics
- Start
- Jan 2026
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of SHR-1819 in atopic dermatitis (AD), sponsored by Hengrui Therapeutics. Started Jan 2026; status: active.
02
Drugs
SHR-1819
03
Conditions
atopic dermatitis (AD)
Beyond the preview
Go deeper on CTR20255128.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20255128.